Macular Edema Incidence/Severity Reduction With Nevanac

NCT00939276 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

175

Enrollment

INDUSTRY

Sponsor class

Stopped Patient recruitment difficulties

Conditions

Diabetic Retinopathy

Interventions

DRUG: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
DRUG: Nepafenac ophthalmic suspension vehicle

Sponsor

Alcon Research